The value of an upper tract urothelial carcinoma MDT: does everyone need a diagnostic ureteroscopy
BAUS ePoster online library. Tay L. Jun 25, 2019; 259487; P12-3
Ms. Li June Tay
Ms. Li June Tay
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)

Upper Tract Urothelial Carcinoma (UTUC) remains a challenging condition to treat due to multiple co-morbidity, radiological uncertainty, difficulty with grade/stage, false negatives, seeding concerns and treatment delays. To address this we implemented an UTUC specialist multidisciplinary team meeting (UTUCMDT) within our existing bladder cancer MDT

In addition to the bladder cancer MDT team, specialist endourologists attend this UTUCMDT. Data was prospectively recorded between January-September2018. Clinical, radiological and pathological features were analysed.


Of 893 cases in the bladder cancer MDT,167 cases (18.7% = 100 patients) were discussed in the UTUCMDT (mean 4.4 cases/meeting). Mean age 67 years (28-92). 48 patients with suspected malignancy underwent a diagnostic ureteroscopy/biopsy (22 benign, 26 malignant). The remaining 52 had diagnosis based on; imaging=37(15 benign, 22 malignant);previous UTUC on surveillance=4, urine tuberculosis culture=1, awaiting further investigations=9, non-urological malignancy=1. 25 patients underwent radical nephroureterectomy(RNU) with only half having a prior ureteroscopy. All RNUs confirmed malignant pathology,2 of which were non-urothelial in nature. Nephron-sparing surgery was attempted in 6 patients. 4 distal ureterectomy, 2 ureteroscopic treatment and subsequent surveillance. 13 patients were managed expectantly for their UTUC due to disease burden or performance status. 2 are undergoing chemotherapy. 3 declined surgery.

Despite current concern regarding the value of MDTs, introduction of a UTUCMDT has streamlined care for this complex and heterogeneous disease in particular reducing the need for ureteroscopy (24(33%) procedures saved if all had undergone ureteroscopy), reducing investigation time without compromising oncological outcomes with no evidence of benign pathology on final RNU.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings